Omitting CTV for Primary Tumor in LS-SCLC

This randomized controlled non-inferior trial prospectively enrolled patients with limited-stage small cell lung cancer (LS-SCLC). Patients in the experimental group would receive radiotherapy with omission of the clinical target volume (CTV) for the primary tumor, while those in the control group would receive radiotherapy including CTV. The efficacy and toxicity of the two groups are compared to provide evidence for the radiotherapy of LS-SCLC. The target volume of LS-SCLC may be reduced by omitting CTV without increasing local recurrence but potentially reducing the dose to organs at risk a

Trial Details

NCT ID
NCT07008716
Phase
PHASE3
Sponsor
Sun Yat-sen University
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Radiation Therapy
  • Etoposide + carboplatin; Etoposide + cisplatin
  • Creating CTV for primary tumor
  • prophylactic cranial irradiation (PCI)
Locations (sample)
  • Guangzhou, Guangdong, China|23.11667,113.25
  • Hangzhou, Zhejiang, China|30.29365,120.16142

Key Eligibility Criteria

  • Small cell lung cancer confirmed by histology or cytology; TNM stage IA-IIIC (AJCC 8th edition, 2017; limited-stage) without intrapulmonary metasta…
  • Aged 18-75 years, KPS score ≥ 80, ≤ 10% weight loss within the past 6 months;
  • Have measurable lesions per RECIST 1.1 criteria;
  • Have no disease progression after 2-4 cycles of etoposide/carboplatin or etoposide/cisplatin;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →